Radiotherapy & Oncology
Volume 93, Issue 3 , Pages 488-491 , December 2009

Weekly paclitaxel with concurrent radiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma

  • Wei Hu

      Affiliations

    • Radiation Oncology Department, Taizhou Hospital, Wenzhou Medical College, Taizhou, China
    • Corresponding Author InformationCorresponding author. Address: Radiation Oncology Department, Taizhou Hospital of Zhejiang Province, 150 Ximen, Linhai, Zhejiang Province 317000, China.
    • ,
  • Weijun Ding

      Affiliations

    • Radiation Oncology Department, Taizhou Hospital, Wenzhou Medical College, Taizhou, China
    • ,
  • Haihua Yang

      Affiliations

    • Radiation Oncology Department, Taizhou Hospital, Wenzhou Medical College, Taizhou, China
    • ,
  • Minghai Shao

      Affiliations

    • Radiation Oncology Department, Taizhou Hospital, Wenzhou Medical College, Taizhou, China
    • ,
  • Biyun Wang

      Affiliations

    • Radiation Oncology Department, Taizhou Hospital, Wenzhou Medical College, Taizhou, China
    • ,
  • Jianhua Wang

      Affiliations

    • Radiation Oncology Department, Taizhou Hospital, Wenzhou Medical College, Taizhou, China
    • ,
  • Sufang Wu

      Affiliations

    • Radiation Oncology Department, Taizhou Hospital, Wenzhou Medical College, Taizhou, China
    • ,
  • Shixiu Wu

      Affiliations

    • Radiation Oncology Department, The First Affiliated Hospital, Wenzhou Medical College, Wenzhou, China
    • ,
  • Lihui Jin

      Affiliations

    • Radiation Oncology Department, Fox Chase Cancer Center, Philadelphia, PA, USA
    • ,
  • Charlie C.-M. Ma

      Affiliations

    • Radiation Oncology Department, Fox Chase Cancer Center, Philadelphia, PA, USA

Received 28 November 2008 ,Revised 9 June 2009 ,Accepted 27 June 2009.

References 

  1. Sanguineiti G, Geara FB, Garden AS, et al. Carcinoma of nasopharynx treated by radiotherapy alone: determinants of local and region control. Int J Radiat Oncol Biol Phys. 1997;37:985–996
  2. Lee AW, Poon YF, Foo W, et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976–1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys. 1992;23:261–270
  3. Baujat B, Audry H, Bourhis J, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys. 2006;64:47–56
  4. Lee K, Hee S, Wee J. The role of adjuvant chemotherapy after concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2007;69:s424–s425
  5. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup Study 0099. J Clin Oncol. 1998;16:1310–1317
  6. Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union Against Cancer Stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol. 2005;23:6730–6738
  7. Lin JC, Jan JS, Hsu CY, et al. Concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol. 2003;21:631–637
  8. Kwong DLW, Sham JST, Au GKH, et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J Clin Oncol. 2004;22:2643–2653
  9. Chan ATC, Leung SF, Ngan RK, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2005;97:536–539
  10. Tishler R, Geard C, Hall E, et al. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res. 1992;52:3495–3497
  11. Dunphy FR, Dunleavy TL, Harrison BR, et al. Induction paclitaxel and carboplatin for patients with head and neck carcinoma. Analysis of 62 patients treated between 1994 and 1999. Cancer. 2001;91:940–948
  12. Suntharalingam M, Haas ML, Conley BA, et al. The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys. 2000;47:49–56
  13. Milas L, Hunter NR, Mason KA, et al. Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel. Cancer Res. 1994;54:3506–3510
  14. Milas L, Hunter NR, Mason KA, et al. Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res. 1995;55:3564–3568
  15. Chen M, Wu SX, Chen YY, et al. Radiation therapy concurrent with weekly paclitaxel for locoregionally advanced nasopharyngeal carcinoma outcomes of a phase I trial. Am J Clin Oncol. 2004;27:481–484
  16. Langendijk JA, Leemans ChR, Buter J, et al. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol. 2004;22:4604–4612
  17. O’Sullivan B. Nasopharynx cancer: therapeutic value of chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2007;69:s118–s121
  18. Chen Y, Liu MZ, Liang SB, et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of China. Int J Radiat Oncol Biol Phys. 2008;71:1356–1364
  19. Lee AW, Lau WH, Tung SY, et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol. 2005;23:6966–6975
  20. Lee AW, Tung SY, Chan AT, et al. Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006;66:142–151
  21. Agarwala SS, Cano E, Heron DE, et al. Long-term outcomes with concurrent carboplatin, paclitaxel and radiation therapy for locally advanced, inoperable head and neck cancer. Ann Oncol. 2007;18:1224–1229
  22. Worden FP, Moon J, Samlowski W, et al. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007. Cancer. 2006;107:319–327
  23. Milross CG, Mason KA, Hunter NR, et al. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst. 1996;88:1308–1314
  24. Belotti D, Vergani V, Drudis T, et al. The microtuble-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res. 1996;2:1843–1849
  25. Chen CY, Lu TX, Zhao C, et al. Weekly paclitaxel with concurrent intensity-modulated radiotherapy for nasopharyngeal carcinoma: outcomes of a tolerance trial. Ai Zheng. 2007;26:398–402
  26. Fountzilas G, Tolis C, Kalogera-Fountzila A, et al. Induction chemotherapy with cisplatin, epirubicin, and paclitaxel (CEP), followed by concomitant radiotherapy and weekly paclitaxel for the management of locally advanced nasopharyngeal carcinoma. Strahlenther Onkol. 2005;181:223–230

PII: S0167-8140(09)00340-5

doi: 10.1016/j.radonc.2009.06.030

Radiotherapy & Oncology
Volume 93, Issue 3 , Pages 488-491 , December 2009

Article Tools

* Image Usage & Resolution